🍪 The GLP Lounge uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsCardiovascular OutcomesSOUL trial preliminary data — 6 month update Page 2

SOUL trial preliminary data — 6 month update

pete_RVA Mon, Oct 27, 2025 at 8:34 PM 9 replies 1,081 viewsPage 2 of 2
VendorMark
Senior Member
3,456
14,567
Jan 2024
Texas
Online
Oct 28, 2025 at 4:00 PM#6
LarryQC_SD said:
Relative and absolute effects need reading together.

I read this differently from LarryQC_SD, on substance rather than tone. I would add the less popular caveat: these trial populations under-represented several groups, older adults and the highest BMI categories among them. The results probably generalise, and "probably" should be stated as an assumption rather than dropped.

Last edited: Oct 28, 2025 at 6:00 PM
12 15DebRD_ATL, KristenIndy, MarkLI_maint and 9 others
Reply Quote Save Share Report
PeptideChemSF
Senior Member
1,890
9,012
Jan 2024
San Francisco, CA
Oct 28, 2025 at 11:43 PM#7
pete_RVA said:
My own curve sits about four points below the published mean and I spent two months assuming that meant something was wrong with me or with my…

Bayesian meta-analysis perspective on the trial evidence: traditional frequentist meta-analyses report point estimates and confidence intervals. Bayesian approaches provide probability distributions that are more intuitive for clinical decision-making.

For example: "There is a 98.5% probability that semaglutide 2.4mg produces >10% weight loss vs placebo" is more actionable than "RR 3.4, 95% CI 2.8-4.1, p<0.001."

The the trial evidence evidence is strong under both frameworks, but Bayesian analysis better communicates the degree of certainty for individual patient counseling.

13 16dave_SLC, FDA_TrackerJim, ricardo_MIA and 10 others
Reply Quote Save Share Report
LibrarianMeg
Senior Member
1,678
7,890
Mar 2024
Baltimore, MD
Oct 29, 2025 at 7:26 AM#8
VendorMark said:
I would add the less popular caveat: these trial populations under-represented several groups, older adults and the highest BMI categories among them.

Propensity score matching studies and the trial evidence: when RCTs aren't available for a specific question, propensity score-matched observational studies can provide useful evidence.

A recent PSM study of 18,000 GLP-1 users vs matched controls showed reduced MI incidence (HR 0.78) over 4 years of follow-up[1].

These results complement the RCT data and suggest the benefits translate to real-world populations.

References:
[1] Registry-based cohort study, pre-print 2024.
14 17julia.endo, JessicaM_2024, TomFromTexas and 11 others
Reply Quote Save Share Report

PeptideMeter — Independent Peptide Analytics

Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.

View Results
tommy_boulder
Member
234
1,123
Nov 2024
Boulder, CO
Oct 29, 2025 at 3:09 PM#9

Following on from DanielChem_CHI — and this may be the naive question:

What would you measure differently if you were starting again?

Last edited: Oct 29, 2025 at 4:09 PM
15 18dan_philly, MeganSA_TX, LarryQC_SD and 12 others
Reply Quote Save Share Report
pete_RVA
Member
178
890
Dec 2024
Richmond, VA
Oct 31, 2025 at 4:14 AM#10

Closing the loop on my own question.

Follow-up: I read the paper rather than the summary and the qualifier I was missing was in the second paragraph of the results.

47 22Dr.LeslieOBGYN, MikeNYC_runner and 44 others
Reply Quote Save Share Report

Similar Threads

SELECT trial: 20% MACE reduction — mechanistic deep dive7 replies
Semaglutide cardiovascular benefit independent of weight loss11 replies
STEP-HFpEF: semaglutide in heart failure with preserved EF15 replies
GLP-1 and arterial inflammation — hsCRP and IL-6 reduction data18 replies
Lp(a) on GLP-1 agonists — any impact on this risk factor?8 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register